Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2018 KRANKHEITSBILD NETZWERK REGISTRY PROJEKTE ANMELDEN
 
 
  
Pathogenic mechanisms -
--->Aktuelles
[-]Das Projekt
--->Sponsor
--->[+]Vorstand
--->[+]Writing Committee Strategic ...
--->[-]Wissenschaftl. Begutachtung
--->Becanovic
--->Busse
--->Correia Guedes
--->Cubo
--->Frontali
--->Holmans
--->Mariotti
--->Norremolle
--->Reetz
--->Saft
--->van Duijn
--->Valenza
--->Verellen
--->Öffentliche Dokumente
--->Zentrale Koordination
--->Länderkoordination
--->Fellowship Programme
--->[+]Constitution
--->[+]Mitglieder
[-]Standorte
--->[+]Österreich
--->[+]Belgien
--->[+]Tschechische Republik
--->[+]Dänemark
--->[+]Finnland
--->[+]Frankreich
--->[-]Deutschland
--->Koordination
--->Selbsthilfe
--->Standard of Care
--->Aachen
--->Berlin
--->Bochum
--->Bonn
--->Dresden
--->Dinslaken
--->Düsseldorf
--->Erlangen
--->Freiburg
--->Hamburg
--->Hannover
--->HH-Heiligenhafen
--->Itzehoe
--->Kassel
--->[+]Lübeck
--->Marburg-KPP
--->Mainz
--->München
--->München-LMU
--->Münster
--->Rostock
--->Taufkirchen
--->Ulm
--->[+]Würzburg
--->[+]Ireland
--->[+]Italien
--->[+]Niederlande
--->[+]Norwegen
--->[+]Polen
--->[+]Portugal
--->[+]Russia
--->[+]Spanien
--->[+]Schweden
--->[+]Schweiz
--->[+]U.K.
--->[+]Outside Europe
[-]Arbeitsgruppen
--->[+]Advanced HD
--->[+]Psychiatrischer Phänotyp
--->[+]Biologische Modifizierer
--->[+]Biomarker
--->[+]Hirngewebedatenbank
--->[+]Kognitiver Phänotyp
--->[+]Environmental Modifiers
--->[+]Funktionelle Fähigkeit
--->[+]Genetische Tests/Beratung
--->[+]Modifizierende Gene
--->[+]Gesundheitsökonomie
--->[+]Bildgebende Verfahren
--->[+]Juvenile HK
--->[+]Motorischer Phänotyp
--->[+]Neuroprotektive Therapie
--->[-]Physiotherapie
--->Termine
--->[-]Meetings
--->Meeting 2008/05
--->Meeting 2008/09
--->Meeting 2009
--->Meeting 2012
--->Meeting 2014
--->Meeting 2015
--->Meeting 2016
--->Call 2017 Subgroup Guide...
--->Meeting 2018
--->[-]Lebensqualität
--->[+]Termine
--->[-]Treffen
--->Treffen 2005/03
--->Treffen 2005/09
--->Treffen 2006/07
--->Treffen 2006/12
--->Treffen 2007/09
--->Treffen 2008/08
--->Treffen 2008/09
--->Treffen 2009/11
--->Meeting 2010/05
--->Meeting 2016/09
--->Meeting 2017/07
--->[+]Behandlungstandards
--->[+]Chirurgische Ansätze
--->[+]Symptomatische Therapie
--->[+]Young Adults
[-]Veranstaltungen
--->[-]EHDN 2018
--->Announcement
--->Introduction
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Registration
--->Sponsoring/Partners
--->CME points
--->HD on the Move
--->Travel Information
--->Hotel booking
--->Flight booking
--->ACV Security Checks
--->About Vienna
--->Useful information
--->Contacts
--->Reimbursement
--->[+]Abstract Submission
--->Documents
--->Feedback
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[-]EHDN 2007
--->Programm
--->Zusätzliche Treffen
--->Tagungsort
--->[-]Über Dresden
--->Kulturelles
--->Sehenswürdigkeiten
--->Essen & Trinken
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Kommunikation
--->Stellenangebote
DatumBeschreibungGrößeAutor Dokument 
06.12.12A framework for cross-species data integration, model sensitivity analysis and target prioritisation in Huntington’s disease using bionetworks1.4 MBblankinapplication/pdfb01-framework-cross-species-data-integ... 
06.12.12Huntington’s disease and its therapeutic target genes: a global functional profile based on the HD research crossroads database1.1 MBblankinapplication/pdfb02-huntington’s-disease-and-its-thera... 
06.12.12Systematic interactome mapping: understanding the molecular principles of neurodegenerative diseases2.1 MBblankinapplication/pdfb03-systematic-interactome-mapping 
06.12.12AMPK activation alleviates phenotypes associated to the early phases of mutant polyQ cytoxicity1.6 MBblankinapplication/pdfb04-ampk-activation 
06.12.12CAG profiling in R6/1 89Q indicates early and progressive expansion in critical neuronal populations and expansion and changes in surrounding glial cell populations2.1 MBblankinapplication/pdfb05-cag-profiling-in-r61-89q 
06.12.12Genotoxic stress in fibroblasts and mesenchymal stem cells isolated from miniature pigs transgenic for n-terminal part of mutated human huntingtin1.3 MBblankinapplication/pdfb06-genotoxic-stress-fibroblasts-mesen... 
06.12.12Analysis of Huntingtin protein fragments in post mortem human Huntington's Disease brain tissue1.8 MBblankinapplication/pdfb07-protein-fragments-post-mortem-human 
06.12.12Differential sensitivity of aggregate markers in HdhQ150 and YAC128 HD mouse models1.6 MBblankinapplication/pdfb08-differential-sensitivity-of-aggreg... 
06.12.12Caspase-6 does not contribute to the proteolysis of mutant Huntingtin in the HDHQ150 knock-in mouse model of Huntington's Disease1.5 MBblankinapplication/pdfb09-caspase-6 
06.12.12The role of N-terminal phosphorylation in Huntingtin´s oligomerization, aggregation and toxicity2.0 MBblankinapplication/pdfb10-n-terminal-phosphorylation 
06.12.12HDAC4 interacts with Huntingtin and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models1.6 MBblankinapplication/pdfb11-hdac4-interacts-with-huntingtin 
06.12.12Long-term alterations in dendritic spine stability in Huntington Disease: Mechanisms underlying learning deficits in Huntington Disease?687 kBblankinapplication/pdfb12-mechanisms-underlying-learning-def... 
06.12.12Huntingtin mediates anxiety/depression-related behaviors in mouse through BDNF transport and hippocampal neurogenesis1.6 MBblankinapplication/pdfb15-bdnf-transport-hippocampal-neuroge... 
06.12.12CTCF in Huntington’s Disease2.0 MBblankinapplication/pdfb16-ctcf-in-hd 
06.12.12Collapsin response mediator protein 4 downregulates aggregation and toxicity of mutant huntingtin1.5 MBblankinapplication/pdfb17-collapsin-response-mediator-protei... 
06.12.12Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation1.6 MBblankinapplication/pdfb18-delaying-aging-and-aging-associate... 
06.12.12Glucose metabolism is reduced in Huntington Disease: in-vivo and in-vitro evidence559 kBblankinapplication/pdfb19-glucose-metabolism 
06.12.12Lactate metabolism in the Huntington's Disease mouse model R6/21.7 MBblankinapplication/pdfb20-lactate-metabolism 
06.12.12Increased glucose uptake in white adipose tissue of R6/2 mice due to changes in expression and translocation of glucose transporter 4 (GLUT4)1.7 MBblankinapplication/pdfb21-increased-glucose-uptake-white-adi... 
06.12.12Decreased expression and reduced translocation to the sarcolemma of the insulin-sensitive glucose transporter GLUT4 in skeletal muscle of R6/2 mice1.4 MBblankinapplication/pdfb22--reduced-translocation-sarcolemma 
06.12.12Does a peripheral immune response influence muscle pathology in Huntington’s Disease?1.6 MBblankinapplication/pdfb23-peripheral-immune-response-muscle-... 
06.12.12Immune dysfunction in HD human myeloid cells is caused by NFkB pathway dysregulation and is reversed by lowering HTT levels1.1 MBblankinapplication/pdfb24-immune-dysfunction-in-hd-human-mye... 
06.12.12Dysfunctional dopaminergic neurones and biphasic activitydependent dopamine release in mouse models of Huntington’s Disease1.5 MBblankinapplication/pdfb25-dysfunctional-dopaminergic-neurone... 
06.12.12Hyperdopaminergic status in Huntington's Disease1.6 MBblankinapplication/pdfb26-hyperdopaminergic-status-in-hd 
06.12.12Sleep and EEG abnormalities in Huntington’s Disease mice1.6 MBblankinapplication/pdfb27-sleep-and-eeg-abnormalities 
06.12.12Neural mechanisms underlying the dysfunction of the methamphetamine-sensitive circadian oscillator (MASCO) in a mouse model of Huntington’s Disease2.1 MBblankinapplication/pdfb29-neural-mechanisms-dysfunction-masco 
06.12.12Voluntary exercise improves circadian function in a mouse model of Huntington’s Disease1.5 MBblankinapplication/pdfb30-circadian-function-in-mouse-model 
06.12.12Expression of mutant Huntingtin in leptin receptorexpressing neurons does not influence the metabolic phenotype and psychiatric-like features in Huntington’s Disease1.6 MBblankinapplication/pdfb31-expression-of-mutant-huntingtin-le... 
06.12.12Deletion of mutant Huntingtin expression in Sim1 neurons in the BACHD mouse model of Huntington's Disease1.5 MBblankinapplication/pdfb32-deletion-of-mutant-huntingtin-expr... 
06.12.12Copy number variation of the neuronal glucose transporter 3 and age of onset in Huntington’s Disease1.5 MBblankinapplication/pdfb0x-neuronal-glucose-transporter-3 
06.12.12Components of the translational machinery modify toxicity in models of Huntington’s Disease1.5 MBblankinapplication/pdfb0y-translational-machinery-modify-tox... 

Verzeichnis enthält 31 Dokumente.
impressum | datenschutz | haftungsausschluss | nutzungsbedingungen